Pande Atul 4
4 · Immunovant, Inc. · Filed Apr 9, 2026
Research Summary
AI-generated summary of this filing
Immunovant (IMVT) Director Atul Pande Receives RSU and Option Awards
What Happened
Atul Pande, a director of Immunovant, was granted two equity awards on April 7, 2026: 13,880 restricted stock units (RSUs) and 7,061 derivative option-based awards. Both grants were recorded at a $0.00 per-share acquisition price (standard for compensation awards), so no cash changed hands in this filing.
Key Details
- Transaction date: April 7, 2026; Form 4 filed April 9, 2026 (timely within the two-business-day reporting window).
- Awards: 13,880 RSUs (non‑derivative) and 7,061 option-based/derivative awards; reported price $0.00, total reported value $0 for both lines.
- Vesting: Both awards vest in full on April 1, 2027, subject to Pande’s continuous service through that date. RSUs can be deferred upon vesting under Rule 409A (per filing footnote).
- Shares owned after the transaction: Not specified in the filing excerpt.
- Transaction code: A = Award/Grant. No 10b5-1 plan, tax‑withholding, cashless exercise, or late‑filing flags noted in the filing.
Context
These grants are standard equity compensation for a board member and are contingent on continued service through the vesting date; they are not an immediate market purchase or sale. RSUs convert to common stock only upon vesting, and the option-based awards’ underlying shares also vest on April 1, 2027 — neither results in immediate proceeds unless subsequently exercised or sold. Such grants are common and should be interpreted as compensation rather than a direct insider buy/sell signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-07+13,880→ 116,731 total - Award
Stock Option (right to buy)
[F2]2026-04-07+7,061→ 7,061 totalExercise: $24.61Exp: 2036-04-07→ Common Stock (7,061 underlying)
- 20,000(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
- [F2]These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.